(ESTA) Establishment Labs Holdings - Ratings and Ratios
Breast Implants, Tissue Expanders
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 70.7% |
| Value at Risk 5%th | 104% |
| Relative Tail Risk | -10.68% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.94 |
| Alpha | 34.82 |
| CAGR/Max DD | 0.01 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.395 |
| Beta | 1.882 |
| Beta Downside | 1.881 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.43% |
| Mean DD | 36.43% |
| Median DD | 41.11% |
Description: ESTA Establishment Labs Holdings November 16, 2025
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a Costa-Rica-based medical-technology firm that designs, manufactures, and markets silicone gel-filled breast implants (Motiva) and breast tissue expanders for aesthetic and reconstructive plastic surgery.
The company distributes its products globally-through a mix of regional distributors and a direct sales force-to physicians, hospitals, and clinics across Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America.
Key recent metrics: 2023 revenue was approximately $140 million, representing a 7 % year-over-year increase driven by higher adoption of premium-segment implants; the firm posted a net loss of $12 million, reflecting ongoing R&D and marketing spend to expand market share in the high-growth cosmetic surgery market, which is projected to expand at a 6 % CAGR through 2028.
Sector drivers that materially affect ESTA’s outlook include rising disposable income in emerging markets, an aging population seeking reconstructive procedures, and a regulatory environment that increasingly favors FDA-cleared, high-safety-profile devices-areas where Motiva’s “silicone-gel-plus” technology is positioned as a differentiator.
For a deeper quantitative assessment, you may find ValueRay’s platform useful for exploring ESTA’s valuation metrics and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-83.0m TTM) > 0 and > 6% of Revenue (6% = 11.5m TTM) |
| FCFTA -0.23 (>2.0%) and ΔFCFTA -0.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 87.77% (prev 86.53%; Δ 1.24pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.21 (>3.0%) and CFO -71.4m > Net Income -83.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.33 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (29.6m) change vs 12m ago 6.15% (target <= -2.0% for YES) |
| Gross Margin 68.74% (prev 65.08%; Δ 3.66pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 61.45% (prev 54.15%; Δ 7.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.42 (EBITDA TTM -48.1m / Interest Expense TTM 24.0m) >= 6 (WARN >= 3) |
Altman Z'' -2.97
| (A) 0.49 = (Total Current Assets 239.6m - Total Current Liabilities 72.0m) / Total Assets 338.9m |
| (B) -1.46 = Retained Earnings (Balance) -493.1m / Total Assets 338.9m |
| warn (B) unusual magnitude: -1.46 — check mapping/units |
| (C) -0.19 = EBIT TTM -58.1m / Avg Total Assets 310.8m |
| (D) -0.20 = Book Value of Equity -65.6m / Total Liabilities 322.5m |
| Total Rating: -2.97 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 22.10
| 1. Piotroski 2.50pt |
| 2. FCF Yield -3.45% |
| 3. FCF Margin -40.59% |
| 4. Debt/Equity 15.96 |
| 5. Debt/Ebitda -3.96 |
| 6. ROIC - WACC (= -34.70)% |
| 7. RoE -253.8% |
| 8. Rev. Trend 47.46% |
| 9. EPS Trend 5.38% |
What is the price of ESTA shares?
Over the past week, the price has changed by +4.34%, over one month by +8.82%, over three months by +84.94% and over the past year by +63.46%.
Is ESTA a buy, sell or hold?
- Strong Buy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ESTA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 74.2 | 4.9% |
| Analysts Target Price | 74.2 | 4.9% |
| ValueRay Target Price | 83.5 | 18% |
ESTA Fundamental Data Overview December 06, 2025
P/S = 10.759
P/B = 120.3301
Beta = 1.057
Revenue TTM = 191.0m USD
EBIT TTM = -58.1m USD
EBITDA TTM = -48.1m USD
Long Term Debt = 246.5m USD (from longTermDebt, last quarter)
Short Term Debt = 11.7m USD (from shortTermDebt, last quarter)
Debt = 261.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 190.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.25b USD (2.05b + Debt 261.2m - CCE 70.6m)
Interest Coverage Ratio = -2.42 (Ebit TTM -58.1m / Interest Expense TTM 24.0m)
FCF Yield = -3.45% (FCF TTM -77.5m / Enterprise Value 2.25b)
FCF Margin = -40.59% (FCF TTM -77.5m / Revenue TTM 191.0m)
Net Margin = -43.45% (Net Income TTM -83.0m / Revenue TTM 191.0m)
Gross Margin = 68.74% ((Revenue TTM 191.0m - Cost of Revenue TTM 59.7m) / Revenue TTM)
Gross Margin QoQ = 70.09% (prev 68.76%)
Tobins Q-Ratio = 6.63 (Enterprise Value 2.25b / Total Assets 338.9m)
Interest Expense / Debt = 2.38% (Interest Expense 6.20m / Debt 261.2m)
Taxrate = -3.95% (negative due to tax credits) (424.0k / -10.7m)
NOPAT = -60.4m (EBIT -58.1m * (1 - -3.95%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.33 (Total Current Assets 239.6m / Total Current Liabilities 72.0m)
Debt / Equity = 15.96 (Debt 261.2m / totalStockholderEquity, last quarter 16.4m)
Debt / EBITDA = -3.96 (negative EBITDA) (Net Debt 190.5m / EBITDA -48.1m)
Debt / FCF = -2.46 (negative FCF - burning cash) (Net Debt 190.5m / FCF TTM -77.5m)
Total Stockholder Equity = 32.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.49% (Net Income -83.0m / Total Assets 338.9m)
RoE = -253.8% (Net Income TTM -83.0m / Total Stockholder Equity 32.7m)
RoCE = -20.81% (EBIT -58.1m / Capital Employed (Equity 32.7m + L.T.Debt 246.5m))
RoIC = -22.93% (negative operating profit) (NOPAT -60.4m / Invested Capital 263.3m)
WACC = 11.77% (E(2.05b)/V(2.32b) * Re(12.95%) + D(261.2m)/V(2.32b) * Rd(2.38%) * (1-Tc(-0.04)))
Discount Rate = 12.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.61%
Fair Price DCF = unknown (Cash Flow -77.5m)
EPS Correlation: 5.38 | EPS CAGR: 5.54% | SUE: 0.56 | # QB: 0
Revenue Correlation: 47.46 | Revenue CAGR: 11.87% | SUE: 1.56 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.46 | Chg30d=+0.070 | Revisions Net=+2 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.87 | Chg30d=+0.021 | Revisions Net=-1 | Growth EPS=+52.6% | Growth Revenue=+24.9%
Additional Sources for ESTA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle